Dance Fever: A Recap of Recent BPCIA Litigation

U.S. Biosimilar Litigation News

With the Supreme Court’s pending decision in Sandoz v. Amgen, the interpretation of the patent dance provisions of the BPCIA has been a hot topic here on the blog.  For an in-depth analysis of patent dance strategies employed by biosimilar applicants to date, check out this article in Bloomberg’s Life Sciences Law & Industry Report written by BMW editors Alexandra Valenti, Alexandra Lu, Elaine Blais, and Rob Cerwinski.

Download PDF

Comments are closed.